Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Breast and Gynecologic Cancer Research Group

Publications

View All  |  2014-2010  |  2009-2004

  • Chun J, Schnahel F, Ogunyemi O. Assessment of breast cancer risk prediction models in a high-risk population. Cancer Res. 2009 Feb 19;69(2)Supplement 1; SABCS-4074.
  • Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B. Randomized Double-Blind 2 X 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women. J Clin Oncol. 2009 Aug 10;27(23):3749-56.
    [ PubMed Abstract ]
  • Eng-Wong J, Reynolds JC, Venzon D, Wedam S, Prindiville S, Zujewski JA, Korde L. Effect of exemestane on bone mineral density in postmenopausal women at increased risk for breast cancer. Cancer Res. 2009 Feb19 69(2)Supplement 2; SABCS-5086.
  • Fabian CJ, Khan QJ, Sharma P, Baxa S, Metheny T, Zalles CM, Kimler BF. Evaluation of Ki-67 measured in benign breast tissue acquired from premenopausal women treated with a flaxseed derivative. J Clin Oncol. 2009 27(15):1507.
  • Heckman-Stoddard BM, Vargo-Gogola T, McHenry PR, Jiang V, Herrick MP, Hilsenbeck SG, Settleman J, Rosen JM. Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res. 2009;11(4):R61.
    [ PubMed Abstract ]
  • Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3. Clin Cancer Res. 2009 Jan 1;15(1):361-7.
    [ PubMed Abstract ]
  • Galgano MT, Castle PE, Stoler MH, Solomon D, Schiffman M. Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Am J Clin Pathol. 2008 Jul;130(1):65-70.
    [ PubMed Abstract ]
  • Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, González P, Porras C, Jiménez S, Guillen D, Morales J, Alfaro M, Cyr J, Morrisey K, Estrada Y, Cortés B, Morera LA, Freer E, Schussler J, Schiller J, Lowy D, Schiffman M ; Costa Rica Vaccine Trial (CVT) Group. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008 Sep 2;26(37):4795-808.
    [ PubMed Abstract ]
  • Lin MC, Lomo L, Baak JP, Eng C, Ince TA, Crum CP, Mutter GL. Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod Pathol. 2009 Feb;22(2):167-74.
    [ PubMed Abstract ]
  • Mutter GL, Kauderer J, Baak JP, Alberts D ; Gynecologic Oncology Group. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Hum Pathol. 2008 Jun;39(6):866-74.
    [ PubMed Abstract ]
  • Nayar R, Solomon D. Support from authors of the Bethesda system. Cytopathology., 2008 Jun;19(3):137-57.
    [ PubMed Abstract ]
  • Windram OP, Weber B, Jaffer MA, Rybicki EP, Shepherd DN, Varsani A. An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins. Arch Virol. 2008 153(3):585-9.
    [ PubMed Abstract ]
  • Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res. 2007 13(16):4943-4948.
    [ PubMed Abstract ]
  • Brown P, Arun B, Miller A, Isaacs C, Gutierrez C, Huang J, Mohsin S, Sneige N, Kim H, Sexton K, Weiss H, Hilsenbeck S, Lamph W, Negro-Vilar A, Johnson K, Elledge R. Prevention of breast cancer using rexinoids: results of a phase II biomarker modulation trial using bexarotene in women at high risk of breast cancer. Breast Cancer Res Treat. 2007 106:S181-S182.
  • Carreon J, Sherman ME, Guillen D, Solomon D, Herrero R et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007 Oct;26:441-6.
    [ PubMed Abstract ]
  • Castle P, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007 Oct;197(4):356.e1-6.
    [ PubMed Abstract ]
  • Fabian CJ, Kimler BF, Mayo MS, Zalles CH, Khan SA, Dooley WC, Krontiras H, Browne D. Phase II tissue-based biomarker prevention trial of celecoxib in premenopausal women at high risk for development of breast cancer. Breast Cancer Res Treat. 2007 106:S179-S179.
  • Hildesheim A, Herrero R, Wacholder S, Rodrigues AC, Solomon D, et al. Effect of Human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. JAMA. 2007 Aug 15;298(7):743-53.
    [ PubMed Abstract ]
  • Kelloff GJ, Sullivan DC, Baker H, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007 3(1):1-33.
  • Lord SJ, Bernstein L, Johnson K, Malone K, Weiss L, McDonald J, Ursin G. Parity, breastfeeding and breast cancer risk by hormone receptor status in women with late age at first birth - a case-control study. Proc. American Association for Cancer Research. 2007 48:622(Abstract #2610).
  • Macis D, Gandini S, Johansson A. COMT V158M, mammographic density and circulating sex hormones in a randomized, double-blind 2 x 2 phase II trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. Frontiers in Cancer Prevention Research, Programs and Proceedings. 2007 Abstract B105;152.
  • Safaeian M, Solomon D. Cervical cancer prevention–cervical screening: science in evolution. In: Obstetrics and Gynecology Clinics of North America. Philadelphia, PA: Saunders; 2007.
    [ PubMed Abstract ]
  • Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with HPV-negative atypical squamous cells of undetermined significance. Obstet Gynecol. 2007 Jun;109(6):1325-31.
    [ PubMed Abstract ]
  • Sherman ME, das Gupta A, Schiffman M, Nayar R, Solomon D. Bethesda Interobserver Reproducibility Study (BIRST). Cancer Cytopathol. 2007;111:15-25.
  • Solomon D, Breen N, McNeel T. Cervical cancer screening rates and potential impact of implementation of screening guidelines. CA Cancer J Clin. 2007 57:105-11.
  • Solomon D, Stoler M, Jeronimo J, Khan M, Castle P, Schiffman M. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low grade cytologic abnormalities. Obstet Gynecol. 2007 Aug;110(2 Pt 1):288-95.
    [ PubMed Abstract ]
  • Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007 127:335-7.
  • Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007 Oct;197(4):340-5.
    [ PubMed Abstract ]
  • Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007 Oct;197:346-55.
    [ PubMed Abstract ]
  • Arun B, Valero V, Yin G, Babiera G, Murray JL, Browne D, Gong Y, Cook E, Hortobagyi GN, Sneige N. Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for breast cancer. J Clinl Oncol. 2006 24(18):51S-51S.
  • Chamberlain CS, Schmetze KH, Anderson JR, Khan SA, Dooley WC, Krontiras H, Browne D, Kimler BF, Fabian CJ. High risk women report minimal pain rating score with random periareolar fine needle aspirations compared to ductal lavage. 29th SABCS 2006.
  • Chatterton RT Jr, Zujewski J, Mateo ET, Eng-Wong J, Jordan VC. Effect of raloxifene on salivary sex steroid concentrations in premenopausal women. J Endocrinol. 2006 Dec;191(3):599-604.
    [ PubMed Abstract ]
  • Fabian CJ, Kimler, Anderson JR, Chamberlain C, Mayo MS, Khan SA, Dooley WC, Krontiras N, Browne D. Comparison of efficacy of random periareolar fine needle aspiration vs. ductal lavage for acquisition of breast tissue in meeting eligibility requirements for phase II chemoprevention study. 29 th SABCS, 2006.
  • Fabian CJ, Kimler BF, Anderson JR, Chamberlain C, Mayo MS, Zalles CM, O'Shaughnessy JA, Lynch HT, Johnson KA, Browne D. Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene. J Clin Oncol. 2006 24(Suppl 18S)abstract 1001.
  • Foster K. Gynecologic cancers: ovarian and cervical cancer prevention. SoCRA Source: Society of Clinical Research Associates. Issue 48, May 2006.
  • Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, Schiffman M, Solomon D, Jeronimo J; ASCUS LSIL Triage Study (ALTS) Group. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006 Aug;108(2):264-72.
    [ PubMed Abstract ]
  • Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano C, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A. preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol. 2006 24:129-35.
  • Johnson KA. The SERM of My Dreams. J Clin Endocrinol Metab. 2006 91:3754-56.
  • Kim H-T, Duong S, Li Y, Uray I, DeNardo D, Hilsenbeck S, Tsimeizon A, Brown P, Bissonnette R, Lamph W, Johnson K. Discovery of rexinoid-modulated biomarkers in human breast cells using microarrays. Proc. American Association for Cancer Research. 2006 47:917(Abstract #3901).
  • Kimler BF, Fabian CJ, Methany T, Xue Q, Zalles CM, Mayo MS, Khan SA, Dooley WC, Krontiras N, Browne D. Comparison of cytomorphology and immunocytochemistry in breast epithelial cells obtained by random periareolar fine needle aspiration vs ductal lavage. 97th Annual AACR Meeting; 2006 (abstract 1425) p.336.
  • Kimler BF, Ursin G, Fabian CJ, Anderson JR, Chamberlain C, Mayo MS, O'Shaughnessy JA, Lynch HT, Johnson KA, Browne D. Effect of the third generation selective estrogen receptor modulator arzoxifene on mammographic breast density. J Clin Oncol. 2006 24(Suppl 18S):18s(abstract 562).
  • Kreimer AR, Guido R, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeler C, Castle P; the ASCUS-LSIL Triage Study (ALTS) Group. HPV testing following loop electrosurgical excision procedure (LEEP) identifies women at risk for post-treatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev. 2006 15(5):908-14.
    [ PubMed Abstract ]
  • Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; the ALTS Group. Cost effectiveness analysis based on the ASCUS and LSIL Triage Study. J Natl Cancer Inst. 2006 98:92-100.
  • Li Y, Hill J, Zhang Y, Kim H-T, Uray I, Bissonnette R, Lamph W, Johnson K, Brown P. Rexinoids prevent the development of premalignant mammary lesions in MMTV-erbB2 mice. Proc. American Association for Cancer Research. 2006 47:917(Abstract #3899).
  • Mariotto AB, Wesley MN, Cronin KA, Johnson KA, Feuer EJ. Estimates of long-term survival for newly diagnosed cancer patients. Cancer. 2006 106:2039-50.
  • Muss HB, Hunter CP, Johnson KA, editors. Treatment and management of cancer in the elderly. In: Basic and clinical oncology series. New York: Taylor and Francis Group; 2006.
  • Ørbo A, Rise CE, Mutter GL. Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res. 2006 Jun 1;66(11):5613-7.
    [ PubMed Abstract ]
  • Percival SS, Johnson KA, Milner JA. Opportunities and challenges for appropriate nutrition of the elderly cancer patient. In: Muss HB, Hunter CP, Johnson KA, editors. Treatment and management of cancer in the elderly. New York: Taylor and Francis Group; 2006. P.451-70.
  • Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, Hoover RN, Ziegler RG. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr. 2006 Apr;83(4):895-904.
  • Walker JL, Wang SS, Schiffman M, Solomon D; ASCUS LSIL Triage Study Group. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS/LSIL Triage Study. Letter to the Editor. Am J Obstet Gynecol. 2006 Aug;195(2):341-8.
    [ PubMed Abstract ]
  • Zuna RE, Wang SS, Schiffman M, Solomon D. Comparison of human papillomavirus distribution in cytologic subgroups of low-grade squamous intraepithelial lesion. Cancer. 2006 Oct 25;108(5):288-97.
  • Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, Palazzo J, Fiane B, Løvslett K, Burger C, Voorhorst F, Verheijen RH. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. 2005 Jun 1;103(11):2304-12.
    [ PubMed Abstract ]
  • Fabian CJ, Kimler BF, Anderson JR, Chamberlain CS, Mayo MS, Khan SA, Dooley WC, Krontiras H, Browne D. Comparison of random periareolar fine needle aspiration vs. ductal lavage for acquisition of breast tissue in meeting eligibility requirements for a phase II chemoprevention study. Fourth Annual AACR International Conference on Frontiers in Cancer Prevention Research. 2005 (abstract A56), p.83.
  • Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS. Breast cancer chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. J Clin Oncol. 2004 22(14_suppl): 1015.
  • Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res. 2004 Aug 15;10(16):5403-17.
    [ PubMed Abstract ]
  • Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol. 2005 Mar;18(3):324-30.
    [ PubMed Abstract ]
  • Zheng W, Baker HE, Mutter GL. Involution of PTEN-null endometrial glands with progestin therapy. Gynecol Oncol. 2004 Mar;92(3):1008-13.
    [ PubMed Abstract ]

Back to top